Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine

Exclusion Criteria

• •Persons who have received a vaccine containing the DPT classified vaccine;
• •Premature labor (delivery before 37th week of gestation), low birth weight 60 (birth weight \<2500g);
• •Those with abnormal labor and delivery, history of asphyxia rescue, history of neurological damage;
• •Who have had one of the pertussis, diphtheria or tetanus diseases;
• •Who have had household contact with an individual diagnosed with pertussis, diphtheria, or tetanus disease in the past 30 days;
• •Have a history of allergy to vaccines or vaccine components and severe side reactions to vaccines, such as hives, dyspnea, angioneurotic edema, and other allergic reactions;
• •Persons with a history of seizures, convulsions, convulsions, or cerebral palsy; or a history or family history of psychiatric illness; or other progressive neurologic disorders;
• •Have been diagnosed with an immunodeficiency, Human Immunodeficiency Virus (HIV) infection, lymphoma, leukemia, Systemic Lupus Erythematosus (SLE), Juvenile Rheumatoid Arthritis ( Juvenile Rheumatoid Arthritis (JRA) or other autoimmune diseases;
• •Any condition resulting in absence of spleen, defective spleen function;
• •Known or suspected acute illness or severe chronic disease (including: severe respiratory disease, severe cardiovascular disease, liver or kidney disease, severe skin disease, malignancy, etc.); or in an acute exacerbation of a chronic disease;
• •Physician-diagnosed coagulation abnormalities (e.g., coagulation factor deficiencies, coagulopathies, platelet abnormalities) or significant bruising or coagulation disorders;
• •Immunosuppressive or modifying agents, cytotoxic consecutive therapy for more than 10 days (except inhaled and topical steroids) within 2 months prior to receiving the test vaccine;
• •Received blood products (other than hepatitis B immune globulin) within 2 months prior to receiving the test vaccine;
• •Participated or planning to participate in any other drug or vaccine clinical study;
• •Has received an injectable live attenuated vaccine within 14 days or another vaccine within 7 days prior to receiving the test vaccine;
• •Axillary temperature \>37.3°C prior to vaccination;
• •Any other factor that, in the investigator's judgment, makes the subject unsuitable for participation in a clinical trial.
• •Persons who have had a severe allergic reaction following a previous dose of vaccine;
• •Persons with serious adverse reactions causally related to the previous dose of vaccination;